echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 1.5 billion cefixime drugs have welcomed 3 more pharmaceutical companies to pass the evaluation

    1.5 billion cefixime drugs have welcomed 3 more pharmaceutical companies to pass the evaluation

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cefixime is a third-generation oral cephalosporin, which is clinically suitable for bacterial infectious diseases
    caused by cefixime-sensitive streptococcus and influenza bacillus.
    At present, a variety of dosage forms
    have been developed in tablets, capsules, granules and oral liquids.
    On October 25, the State Drug and Drug Administration issued a new batch of drug approval documents to be received, among which many varieties of cefixime drugs were again evaluated by enterprises
    .

     
    Screenshot from the State Drug and Drug Administration
     
    According to this information, cefixime tablets of Shenzhen Lijian Pharmaceutical Co.
    , Ltd.
    , cefixime capsules of Chaohu Jinchen Pharmaceutical Co.
    , Ltd.
    of Shanghai Haihong Industrial (Group), and cefixime dispersible tablets of Sichuan Saizhuo Pharmaceutical Co.
    , Ltd.
    have been evaluated
    .
    The data shows that so far, a total of 38 specifications of cefixime in the domestic cefixime market have passed the consistency evaluation
    .

     
    The data shows that the market demand for cefixime drugs is large, such as the hospital sales of cefixime drugs in 2021 will be 1.
    59 billion yuan
    .
    In addition, data show that in 2021, the sales of cefixime tablets in China's three major terminal markets will exceed 600 million yuan; In 2020, the overall sales scale of cefixime capsules in China will be about 1.
    26 billion yuan
    .

     
    At present, 4 varieties such as cefixime capsules, cefixime granules, cefixime tablets and cefixime dispersible tablets have been evaluated
    by 5-11 companies.
    Among them, 19 companies have production approvals for cefixime tablets, and the currently evaluated enterprises include Jiangsu Zhengda Qingjiang Pharmaceutical, Hunan Sheng Pharmaceutical, Zhejiang Jutai Pharmaceutical and Shenzhen Lijian Pharmaceutical that has recently been evaluated, in addition, Shandong Lukang Pharmaceutical consistency evaluation supplementary application is under review, Wenling Innovative Biomedicine | Wanbangde Pharmaceutical is under review for generic 3 types of production, which is regarded as having been evaluated
    after approval.

     
    Regarding cefixime capsules, in addition to the above-mentioned evaluation of Shanghai Haihong Pharmaceutical, many pharmaceutical companies such as Zhendong Pharmaceutical, CSPC Ouyi Pharmaceutical Co.
    , Ltd.
    , North China Pharmaceutical Hebei Huamin Pharmaceutical Co.
    , Ltd.
    , Qilu Pharmaceutical Co.
    , Ltd.
    , Chengdu Beite Pharmaceutical Co.
    , Ltd.
    , Guangzhou Baiyunshan Pharmaceutical Group Co.
    , Ltd.
    Baiyunshan Pharmaceutical General Factory and Taisheng Pharmaceutical have passed the consistency evaluation
    .

     
    It is reported that at present, 13 specifications of cefixime drugs have been included in the 7th batch of centralized procurement, involving Hunan Sheng Pharmaceutical, Shandong Haishan Pharmaceutical, Zhejiang Jutai Pharmaceutical, Chengdu Beite Pharmaceutical, Jinhong Pharmaceutical, Sinopharm Group Zhijun (Shenzhen) Pharmaceutical, Zhejiang Asia-Pacific Pharmaceutical, Zhejiang Onlikang Pharmaceutical, Kunming Jida Pharmaceutical, North China Pharmaceutical Hebei Huamin Pharmaceutical, Guangdong South China Pharmaceutical Group and many other enterprises
    .

     
    However, from the current point of view, no pharmaceutical companies have evaluated chewable tablets and dry suspensions in cefixime, and only Shenzhen Lijian Pharmaceutical has submitted a supplementary application for consistency evaluation of dry suspensions, which is still under
    review and approval.
    The industry said that the domestic cefixime drug market is fiercely competitive, and there will be companies in the future
    .
    Some enterprises said that the company's products through the consistency evaluation of generic drugs will help expand the market of products and enhance market competitiveness
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.